ACME Laboratories Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 3/6
ACME Laboratories has been growing earnings at an average annual rate of 12.8%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 12.4% per year. ACME Laboratories's return on equity is 10%, and it has net margins of 8.1%.
Key information
12.8%
Earnings growth rate
12.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | 12.4% |
| Return on equity | 10.0% |
| Net Margin | 8.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ACME Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 29,394 | 2,374 | 6,929 | 0 |
| 30 Sep 23 | 28,280 | 2,342 | 6,704 | 0 |
| 30 Jun 23 | 26,948 | 2,304 | 6,424 | 0 |
| 31 Mar 23 | 25,869 | 2,202 | 6,005 | 0 |
| 31 Dec 22 | 25,334 | 2,169 | 5,748 | 0 |
| 30 Sep 22 | 24,506 | 2,144 | 5,574 | 0 |
| 30 Jun 22 | 23,858 | 2,111 | 5,381 | 0 |
| 31 Mar 22 | 23,203 | 1,985 | 5,117 | 0 |
| 31 Dec 21 | 22,386 | 1,872 | 4,855 | 0 |
| 30 Sep 21 | 21,735 | 1,742 | 4,670 | 0 |
| 30 Jun 21 | 20,770 | 1,569 | 4,457 | 0 |
| 31 Mar 21 | 20,341 | 1,503 | 4,146 | 0 |
| 31 Dec 20 | 19,875 | 1,467 | 3,950 | 0 |
| 30 Sep 20 | 19,516 | 1,465 | 3,771 | 0 |
| 30 Jun 20 | 19,004 | 1,450 | 3,551 | 0 |
| 31 Mar 20 | 18,161 | 1,421 | 3,612 | 0 |
| 31 Dec 19 | 17,465 | 1,435 | 3,362 | 0 |
| 30 Sep 19 | 16,859 | 1,452 | 3,120 | 0 |
| 30 Jun 19 | 16,309 | 1,440 | 3,018 | 0 |
| 31 Mar 19 | 15,955 | 1,377 | 3,014 | 0 |
| 31 Dec 18 | 15,542 | 1,400 | 2,935 | 0 |
| 30 Sep 18 | 15,155 | 1,394 | 2,923 | 0 |
| 30 Jun 18 | 14,814 | 1,427 | 2,843 | 0 |
| 31 Mar 18 | 14,708 | 1,449 | 2,789 | 0 |
| 31 Dec 17 | 14,335 | 1,443 | 2,675 | 0 |
| 30 Sep 17 | 13,943 | 1,440 | 2,562 | 0 |
| 30 Jun 17 | 13,576 | 1,398 | 2,522 | 0 |
| 31 Mar 17 | 13,358 | 1,523 | 2,509 | 0 |
| 31 Dec 16 | 13,270 | 1,389 | 2,454 | 0 |
| 30 Sep 16 | 12,967 | 1,250 | 2,385 | 0 |
| 30 Jun 16 | 12,645 | 1,101 | 2,305 | 0 |
| 31 Mar 16 | 12,396 | 990 | 2,072 | 0 |
| 30 Jun 15 | 11,496 | 922 | 1,999 | 0 |
| 30 Jun 14 | 10,218 | 894 | 2,088 | 0 |
| 30 Jun 13 | 9,809 | 525 | 1,926 | 0 |
Quality Earnings: ACMELAB has high quality earnings.
Growing Profit Margin: ACMELAB's current net profit margins (8.1%) are lower than last year (8.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACMELAB's earnings have grown by 12.8% per year over the past 5 years.
Accelerating Growth: ACMELAB's earnings growth over the past year (9.5%) is below its 5-year average (12.8% per year).
Earnings vs Industry: ACMELAB earnings growth over the past year (9.5%) exceeded the Pharmaceuticals industry -2.6%.
Return on Equity
High ROE: ACMELAB's Return on Equity (10%) is considered low.